Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose
Your daily dose of the clinical news you may have missed.
Johann Gudjonsson, MD, PhD: Role of OX-40 Pathway in Atopic Dermatitis Pathogenesis
Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.
Atogepant Superior to Topiramate for Migraine Prevention in Phase 3 Head-to-Head TEMPLE Study
The superior tolerability and efficacy of the CGRP-targeting atogepant supports recent calls from the AHS to consider the class as first-line preventive therapy for migraine.
Validation Study of SANSA Home Sleep Apnea Test Published in Frontiers in Neurology, Huxley Medical Announces
Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.
Universal Low-Dose Aspirin Prescribing Strategy May be Beneficial for Preeclampsia Prevention
Research presented at ACOG 2025 showed 99% of pregnant women included in the analysis were eligible for aspirin, per ACOG guidelines.
On Topical Steroid Withdrawal Syndrome, We Need Bigger Studies, More Clinical Trials: Brad Glick, DO, MPH
The literature on topical steroid withdrawal syndrome is scant, Glick says; we're learning more about it, but we need more research to help our patients.
Early Colorectal Cancer Screening at Ages 40-49 Reduces Long-Term Incidence and Mortality
As the incidence of young-onset colorectal cancer continues to rise, the findings from a large Taiwanese population-based study support lowering the age for initial screening.
Physician Survey Results: Primary Care Knowledge of Screening for Cognitive Decline
New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.
The Future of Atopic Dermatitis Management: Peter Lio, MD, on Preparing for Next-Generation Treatment Strategies
RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.
FDA Accepts NDA for Anaphylm™, a Sublingual Epinephrine Film for Treatment of Severe Allergic Reactions
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.
Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma
EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.
Fecal Microbiota Transplant Found Noninferior to Antibiotic as Initial Treatment for C. Diff
Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.
DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy
For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.
How Americans Think and Feel About Their Medical Devices: New Survey Findings
Among 2000 US adults, a new survey found consumers prioritize trust and recommendations over brand loyalty in health tracking devices, prizing accuracy and reliability.
What, Exactly, is Alcohol Use Disorder?
AUD affects 15 million Americans, with men nearly 2 times more vulnerable to the disease vs women. Are you tracking signs and symptoms in your patients?
Solriamfetol Improves OSA-Related Cognitive Deficits Independent of Sleepiness Reduction
Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.
Topical Steroid Withdrawal vs Atopic Dermatitis Flare: Parsing the Differences with Brad Glick, DO, MPH
RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.
Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma
The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.
Key Updates in Atopic Dermatitis for Primary Care
Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.
Late-Life Mood Disorders Show Strong Association with Tau and Amyloid Pathology, Study Reveals
Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.
